Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
暂无分享,去创建一个
S. Pileri | A. Levis | E. Iannitto | A. Gallamini | L. Rigacci | A. Tucci | A. Pinto | F. Zaja | C. Patti | C. Tarella | A. Manna | A. Billio | P. Torchio | V. Zoli | V. Secondo | M. Specchia
[1] Sukjoong Oh,et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study , 2007, Cancer Chemotherapy and Pharmacology.
[2] S. Pileri,et al. Expression of CD52 in peripheral T-cell lymphoma. , 2007, Haematologica.
[3] A. Horwich,et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. , 2007, Haematologica.
[4] M. Czuczman,et al. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901 , 2007, Leukemia & lymphoma.
[5] J. Kutok,et al. Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H) , 2006, Clinical Cancer Research.
[6] O. O’Connor,et al. Pralatrexate: an emerging new agent with activity in T-cell lymphomas , 2006, Current opinion in oncology.
[7] T. Barbui,et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation , 2006, Leukemia.
[8] A. Zelenetz,et al. Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphoma , 2006, British journal of haematology.
[9] S. Pileri,et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Gisselbrecht,et al. Managing large cell lymphoma. , 2006, Annals of Oncology.
[11] C. Dearden. The role of alemtuzumab in the management of T-cell malignancies. , 2006, Seminars in oncology.
[12] T. Rüdiger,et al. The role of high-dose therapy in peripheral T-cell lymphomas. , 2006, Clinical lymphoma & myeloma.
[13] A. Zelenetz,et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Christian Buske,et al. Treatment strategies in follicular lymphomas: current status and future perspectives. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Scott E. Smith,et al. Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228 , 2005 .
[16] E. Matutes,et al. CD52 expression in T-cell large granular lymphocyte leukemia – Implications for treatment with alemtuzumab , 2005, Leukemia & lymphoma.
[17] A. Gianni,et al. Bone marrow transplantation for lymphoma CR1 , 2005, Current opinion in oncology.
[18] K. Savage. Aggressive peripheral T-cell lymphomas (specified and unspecified types). , 2005, Hematology. American Society of Hematology. Education Program.
[19] V. Kurup,et al. Generation of Th1 T Cell Responses Directed to a HLA Class II Restricted Epitope from the Aspergillus f16 Allergen. , 2004 .
[20] E. Elonen,et al. Tumours of haematopoietic and lymphoid tissues: general guidelines , 2004 .
[21] M. Boccadoro,et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Erlanson,et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. , 2004, Blood.
[23] E. Iannitto,et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.
[24] K. Franssila,et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey , 2004, Bone Marrow Transplantation.
[25] J. Babbage,et al. Assessment of host defence against infection during chemotherapy of Hodgkin's disease , 2004, Cancer Chemotherapy and Pharmacology.
[26] M. Introna,et al. Effect of alemtuzumab on neoplastic B cells. , 2004, Haematologica.
[27] A. F. Sevilla,et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] G. Juliusson,et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. , 2003, Blood.
[29] A. López-Guillermo,et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. , 2003, Haematologica.
[30] B. Nathwani,et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] D. Catovsky,et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. , 2001, Blood.
[32] M. Munsell,et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] N. Nguyen,et al. Treatment of refractory T‐cell malignancies using gemcitabine , 2001, British journal of haematology.
[34] R. A’Hern. Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.
[35] J. Verhaegen,et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. , 2001, Blood.
[36] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. López-Guillermo,et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] S. Pileri,et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. , 1998, Journal of clinical pathology.
[39] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[40] L. Ginaldi,et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. , 1998, Leukemia research.
[41] A. Melnyk,et al. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[42] S. Pileri,et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] T. Habermann,et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] P. Gaulard,et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] R. Fanin,et al. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. , 1997, Haematologica.
[46] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[47] R. Warnke,et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] F. Berger,et al. Original article: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen , 1990 .
[49] Y. C. Chen,et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately? , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] F. Berger,et al. T-cell lymphomas: immunologic, histologic, clinical, and therapeutic analysis of 63 cases. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] W. Hryniuk,et al. The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[53] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .